{"nctId":"NCT00797797","briefTitle":"Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia","startDateStruct":{"date":"2008-11"},"conditions":["Fibromyalgia"],"count":364,"armGroups":[{"label":"Milnacipran Added","type":"EXPERIMENTAL","interventionNames":["Drug: Milnacipran Added"]},{"label":"No Treatment Added","type":"EXPERIMENTAL","interventionNames":["Drug: No Treatment Added"]}],"interventions":[{"name":"No Treatment Added","otherNames":["Lyrica (r)"]},{"name":"Milnacipran Added","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria\n* tolerate at least 300 mg/day of pregabalin\n* have an incomplete response to pregabalin treatment\n\nExclusion Criteria:\n\n* suicidal risk\n* substance abuse\n* pulmonary dysfunction\n* renal impairment\n* active cardiac disease\n* liver disease\n* narrow angle glaucoma\n* autoimmune disease\n* cancer\n* inflammatory bowel disease\n* unstable endocrine disease\n* prostatic enlargement","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patient Global Impression of Change (PGIC) Responder Rate at End of Study","description":"The primary efficacy parameter was the PGIC responder rate, defined as the percentage of patients who rated themselves as \"very much improved\" or \"much improved\" (ie, having a score of 1 or 2 on the 7-point scale) for the PGIC at end of study (Visit 6 or Early Termination) compared to Visit 1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Visual Analog Scale (VAS) 1-week Pain Recall at End of Study","description":"The secondary efficacy measure was the change from Visit 2 (Week 0) in the 1-week pain recall at Visit 6 (Week 11) or End of Study, measured using a 100-mm VAS assessment of pain (0 indicating no pain and 100 indicating the worst possible pain).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.43","spread":"1.93"},{"groupId":"OG001","value":"-20.77","spread":"1.92"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":178},"commonTop":["Nausea","Weight Increased","Fatigue","Oedema peripheral","Headache"]}}}